Selective muscarinic receptor antagonists for airway diseases

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Airway tone and airway hyperreactivity are mediated by the parasympathetic nerves that release acetylcholine onto muscarinic receptors (M1-M5). Stimulation of M1 and M3 muscarinic receptors causes bronchoconstriction. The M1 muscarinic receptor is excitatory, and facilitates neuronal transmission at the parasympathetic ganglion. The M2 receptor is an inhibitory prejunctional autoreceptor. The discovery of discrete muscarinic receptor subtypes prompted development of selective muscarinic receptor antagonists. Selective M3 receptor antagonists and antagonists selective for M1 and M3 receptors have recently entered clinical trials and offer much promise for the treatment of airways diseases.

Original languageEnglish (US)
Pages (from-to)223-229
Number of pages7
JournalCurrent Opinion in Pharmacology
Issue number3
StatePublished - Jun 1 2001
Externally publishedYes


  • Airways disease
  • Antimuscarinic bronchodilator
  • Asthma
  • Chronic obstructive lung disease
  • Molecular Medicine
  • Muscarinic receptor
  • Pharmacology
  • Review
  • Tiotropium

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Selective muscarinic receptor antagonists for airway diseases'. Together they form a unique fingerprint.

Cite this